Skip to main content

Table 1 Multi-Cohort CLL Patient Characteristics by IgHV status*

From: Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia

  

All CLL patients† (% or 95% CI)

XPO1-mut (IgHV-U)† (% or 95% CI)

XPO1-wt (IgHV-U)† (% or 95% CI)

XPO1-wt (IgHV-M)† (% or 95% CI)

p value‡

test

 

Demographics

Gender (n, Male)

649 (69.3%)

41 (75.9%)

349 (71.8%)

258 (65.2%)

0.630

χ2

 

Rai (n, II–IV)

167 (27.4%)

21 (53.8%)

86 (27.6%)

60 (23.3%)

0.199

χ2

 

Age (median, year)

57.2 (56.4–58.0)

52.3 (49.9–55.0)

57.1 (56.0–58.2)

58.7 (57.4–59.9)

0.031

t-test

 

Blood Counts

B2M (median)

3 (2.8–3.2)

3.4 (2.6–4.2)

3.15 (2.9–3.4)

2.7 (2.5–2.9)

0.814

t-test

 

HGB (median)

13.1 (12.9–13.3)

12.5 (11.7–13.3)

13.1 (12.8–13.4)

13.4 (13.1–13.7)

0.562

t-test

 

LDH (median)

493 (463–523)

528 (446–610)

499.5 (453–546)

473 (438–508)

0.809

t-test

 

PLT (median)

167 (159.7–174.3)

140.5 (113.5–167.5)

177 (188–166)

164.5 (154.7–174.3)

0.149

t-test

 

WBC (median)

65.35 (57.67–73.03)

122.95 (82.28–163.62)

72.3 (61.83–83.60)

44.8 (35.59–54.01)

0.041

t-test

 

FISH

del(11q)

74 (15%)

3 (11%)

63 (25%)

8 (4%)

0.081

χ2

 

del(13q)

276 (55%)

20 (74%)

116 (45%)

140 (66%)

0.003

χ2

 

del(17p)

51 (8%)

1 (3%)

40 (12%)

10 (3%)

0.079

χ2

 

12 + 

64 (13%)

0 (0%)

42 (16%)

22 (10%)

0.011

χ2

 

CN

134 (27%)

7 (26%)

71 (28%)

56 (27%)

0.51

χ2

 

Mutation Panel

NOTCH1

99 (9%)

9 (13%)

79 (13%)

11 (3%)

0.52

χ2

 

SF3B1

52 (15%)

8 (30%)

29 (14%)

15 (12%)

0.045

χ2

 

TP53

97 (19%)

5 (16%)

71 (26%)

21 (10%)

0.141

χ2

 

XPO1

72 (6%)

72 (100%)

0 (0%)

0 (0%)

-

-

 

EGR2

46 (4%)

4 (6%)

32 (5%)

10 (2%)

0.51

χ2

 

MYD88

26 (2%)

0 (0%)

2 (0.3%)

24 (6%)

0.81

χ2

 
  

All CLL patients† (% or 95% CI)

XPO1-mut (LP-CLL)† (% or 95% CI)

XPO1-wt (LP-CLL)† (% or 95% CI)

XPO1-wt (IP-CLL)† (% or 95% CI)

XPO1-wt (HP-CLL)† (% or 95% CI)

p value$

Test

 

Multi-Cohort CLL patient characteristics by epigenetic maturation status*

Demographics

Gender (count, M)

659 (69%)

41 (78.8%)

310 (70.9%)

120 (72.7%)

188 (62.5%)

0.130

χ2

Rai (count, > 1)

167 (27.5%)

21 (56.8%)

76 (27%)

36 (35.3%)

34 (18.2%)

0.036

χ2

Age (median, year)

57.2 (56.4–58.0)

52.3 (49.6–55.0)

57.0 (55.8–58.1)

57.1 (55.2–59.1)

59.1 (57.7–60.6)

0.020

t-test

Blood Counts

B2M (median)

3 (2.8–3.2)

3.4 (2.6–4.2)

3.3 (3.0–3.6)

2.9 (2.5–3.3)

2.65 (2.4–2.9)

0.826

t-test

HGB (median)

13.1 (12.9–13.3)

12.1 (11.3–12.9)

13 (12.7–13.3)

13.3 (12.8–13.8)

13.4 (13.1–13.7)

0.440

t-test

LDH (median)

494 (464–524)

545 (459–631)

524 (475–573)

476 (415–537)

459 (422–496)

0.936

t-test

PLT (median)

167 (160–174)

132 (105–159)

176 (165–187)

160 (145–175)

167 (155–179)

0.110

t-test

WBC (median)

65.35 (57.67–73.03)

124 (81.34–166.66)

77.3 (65.49–89.11)

42.45 (26.59–58.31)

43.65 (33.02–54.28)

0.056

t-test

FISH

del(11q)

74 (14%)

2 (8%)

62 (26%)

9 (10%)

1 (1%)

0.064

χ2

del(13q)

288 (56%)

18 (69%)

101 (42%)

64 (72%)

105 (64%)

0.0043

χ2

del(17p)

52 (7%)

1 (3%)

39 (13%)

5 (4%)

7 (3%)

0.196

χ2

12 + 

66 (13%)

0 (0%)

43 (18%)

10 (11%)

13 (8%)

0.006

χ2

CN

140 (27%)

8 (31%)

67 (29%)

18 (20%)

47 (29%)

0.54

χ2

Mutation Panel

NOTCH1

105 (9%)

11 (17%)

75 (13%)

11 (6%)

8 (3%)

0.289

χ2

SF3B1

57 (15%)

7 (25%)

28 (15%)

18 (32%)

4 (4%)

0.131

χ2

TP53

101 (19%)

5 (16%)

68 (28%)

13 (14%)

15 (9%)

0.214

χ2

XPO1

71 (6%)

69 (97%)

0 (0%)

0 (0%)

0 (0%)

–

–

EGR2

48 (4%)

5 (7%)

29 (5%)

9 (5%)

5 (2%)

0.32

χ2

MYD88

27 (2%)

0 (0%)

0 (0%)

14 (7%)

13 (4)

–

–

  1. *Characteristics at time of diagnosis
  2. †Represents the total count of eligible patients with available data for each annotation
  3. ‡p value determined by: XPO1-mut (IgVH-U) vs XPO1-wt (IgVH-U)
  4. $p value determined by: XPO1-mut (LP-CLL) vs XPO1-wt (LP-CLL)